Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer (Q43843193)

27 November 2017

title

Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer (English)

1 reference

27 November 2017

main subject

metastatic breast cancer

1 reference

based on heuristic

inferred from title

author name string

Natasa Todorović-Raković

1

1 reference

27 November 2017

Danica Jovanović

2

1 reference

27 November 2017

Zora Nesković-Konstantinović

3

1 reference

27 November 2017

Dragica Nikolić-Vukosavljević

4

1 reference

27 November 2017

publication date

30 January 2007

1 reference

Experimental and Molecular Pathology

27 November 2017

published in

1 reference

27 November 2017

volume

82

1 reference

27 November 2017

issue

3

1 reference

27 November 2017

page(s)

262-268

1 reference

Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

Facts and controversies in systemic treatment of metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

The association of HER-2/neu amplification with breast cancer recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

Assessment of HER2 status in breast cancer: why, when and how?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

c-erbB-2 in breast cancer: development of a clinically useful marker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

ERBB2 oncogene in human breast cancer and its clinical significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

Accuracy and precision in HER2/neu testing in breast cancer: are we there yet?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2007.01.002

10.1016/J.YEXMP.2007.01.002

7 January 2021

Identifiers

DOI

1 reference

27 November 2017

1 reference